Why the study?
Randomised clinical trial data on the use of MitraClip for mitral regurgitation in Asian-Pacific patients is limited.
This document provides 10 consensus recommendations from the Asian Pacific Society of Cardiology to guide the use of MitraClip for various forms of mitral regurgitation in the region.
Answers are grounded in this paper and cite their sources.
Offers regional consensus guidance for MitraClip in Asia-Pacific MR; leaves open need for prospective regional validation.
Transcatheter mitral valve repair with the MitraClip, a catheter-based percutaneous edge-to-edge repair technique to correct mitral regurgitation (MR), has been demonstrated in Western studies to be an effective and safe MR treatment strategy. However, randomised clinical trial data on its use in Asian-Pacific patients is limited. Hence, the Asian Pacific Society of Cardiology convened an expert panel to review the available literature on MitraClip and to develop consensus recommendations to guide clinicians in the region. The panel developed statements on the use of MitraClip for the management of degenerative MR, functional MR, and other less common indications, such as acute MR, dynamic MR, hypertrophic obstructive cardiomyopathy, and MR after failed surgical repair. Each statement was voted on by each panel member and consensus was reached when 80% of experts voted 'agree' or 'neutral'. This consensus-building process resulted in 10 consensus recommendations to guide general cardiologists in the evaluation and management of patients in whom MitraClip treatment is being contemplated.
No takes yet. Share an insight, caveat, or question.
Yeo et al. (2021) conducted a review in Mitral regurgitation. MitraClip was evaluated. MitraClip evaluation and management for mitral regurgitation in the Asia-Pacific region was outlined in 10 consensus recommendations developed by an expert panel.
Synapse has enriched 10 related papers. Consider them for comparative context: